Bright Minds Biosciences Inc (DRUG)
Healthcare
Biotechnology
73.30 $
-1.8%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Bright Minds Biosciences Inc (DRUG)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 52.3% of the shares are freely tradable; institutional investors hold 92.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
92.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
12.0%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
52.3%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
10.8%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
10Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| HHG PLC | 13.09 | 1,284,324 | +11.1 | 03/31/2026 |
| Cormorant Asset Management, LLC | 10.80 | 1,059,331 | +0.0 | 03/31/2026 |
| BlackRock Inc | 6.34 | 621,933 | +57.8 | 03/31/2026 |
| Vivo Capital, LLC | 5.68 | 557,172 | +11.1 | 03/31/2026 |
| BRAIDWELL LP | 5.50 | 539,708 | +66.4 | 03/31/2026 |
| Adage Capital Partners Gp LLC | 5.05 | 495,743 | +25.3 | 03/31/2026 |
| Vestal Point Capital LP | 5.02 | 492,319 | +0.0 | 03/31/2026 |
| Driehaus Capital Management LLC | 4.41 | 432,515 | +60.4 | 03/31/2026 |
| Perceptive Advisors LLC | 3.85 | 377,544 | -16.0 | 03/31/2026 |
| Balyasny Asset Management LLC | 3.03 | 297,158 | +31.8 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.